Patents by Inventor Sudhir Agrawal

Sudhir Agrawal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220370487
    Abstract: The invention provides therapeutic compositions that include an antisense oligonucleotide (ASO) complementary to an identified target on a Nav channel mRNA. The ASO hybridizes to its target RNA and forms a duplex that recruits RNase H to degrade the RNA, thereby downregulating Nav channel synthesis, which inhibits the neuron's ability to contribute to certain conditions such as epilepsy and pain perception. The ASO binds to one of the specific identified targets, and may be provided as a gapmer that includes a central DNA segment flanked by modified RNA wings.
    Type: Application
    Filed: May 10, 2022
    Publication date: November 24, 2022
    Inventors: Christina Ambrosi, Luis Williams, Caitlin Lewarch, David Gerber, Owen McManus, Sudhir Agrawal, Graham T. Dempsey
  • Publication number: 20220372489
    Abstract: Disclosed herein are inhibitors of PPM 1 A, including PPM1A antisense oligonucleotide sequences, and methods for treating neurological diseases, such as amyotrophic lateral sclerosis and frontotemporal dementia, associated with decreased activity or expression of TBK1.
    Type: Application
    Filed: June 19, 2020
    Publication date: November 24, 2022
    Inventors: Sandra Hinckley, Duncan Brown, Sudhir Agrawal, Daniel Elbaum
  • Publication number: 20220333105
    Abstract: Disclosed herein are antisense oligonucleotide sequences, and methods of use for treating neurological diseases. Described herein are oligonucleotide inhibitors. In various embodiments, the oligonucleotide targets a transcript for the treatment of neurological diseases, including motor neuron diseases, and/or neuropathies. For example, inhibitors of the transcript can be used to treat PD, ALS, FTD, and ALS with FTD.
    Type: Application
    Filed: June 3, 2020
    Publication date: October 20, 2022
    Inventors: Sandra Hinckley, Duncan Brown, Sudhir Agrawal
  • Publication number: 20220327539
    Abstract: The present disclosure generally relates to systems and methods for processing recurring payment transactions. In various embodiments, the system receives details of the set of recurring payment transactions and stores the details in a recurring transaction details table. The system generates a virtual payment instrument and associates it with the consumer's payment instrument. The system transmits the virtual payment instrument to the consumer. The system then generates a set of payment tokens for the set of recurring transactions and links the tokens to the virtual payment instrument. Each token is associated with a discrete recurring period. The system encodes each token with a sequence of values and stores the tokens in the recurring payment token table. The system receives a recurring transaction request that includes the virtual payment instrument. The system validates the request against a token associated with the recurring period, processes the transaction, and deletes the token.
    Type: Application
    Filed: June 20, 2022
    Publication date: October 13, 2022
    Applicant: Mastercard International Incorporated
    Inventors: Harsh Piparsaniya, Sudhir Gupta, Rahul Agrawal
  • Patent number: 11455634
    Abstract: Embodiments provide a method of facilitating a payment transaction with a payment card of a customer. The method includes receiving a payment transaction request initiated at a merchant terminal. The payment transaction request comprises a merchant transaction amount associated with a purchase entered at the merchant terminal and a fingerprint tap input provided by the customer on a fingerprint input module, the fingerprint tap input indicative of a customer transaction amount associated with the purchase. The method includes facilitating verification of a fingerprint obtained from the fingerprint tap input of the customer by comparing with stored fingerprint of the customer. The method further includes, upon successful verification, determining whether the merchant transaction amount conforms to the customer transaction amount obtained from the fingerprint tap input.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: September 27, 2022
    Assignee: MASTERCARD INTERNATIONAL INCORPORATED
    Inventors: Rahul Agrawal, Sudhir Gupta, Harsh Piparsaniya
  • Publication number: 20220282249
    Abstract: The present invention is directed to compounds, compositions, and methods useful for modulating gene splicing. In some embodiments, modulating gene splicing increases expression of a target protein or a target functional RNA.
    Type: Application
    Filed: March 17, 2022
    Publication date: September 8, 2022
    Inventor: Sudhir Agrawal
  • Publication number: 20220259601
    Abstract: The invention provides compositions useful to knock down overexpression of UBE3A and treat conditions associated with Dup15q syndrome. The compositions include antisense oligonucleotides, preferably short oligonucleotides that are complementary to, and hybridize to, UBE3A transcripts in vivo. The ASOs prevent or inhibit successful translation of UBE3A mRNA into protein. Specifically, preferred embodiments include anti-UBE3A gapmersā€”oligos that include a central DNA portion flanked by RNA wings. When the gapmer hybridizes to UBE3A pre-mRNA or mRNA, the duplex hybrid recruits RNaseH, which cleaves, or digests, the UBE3A pre-mRNA or mRNA, preventing expression of the UBE3A protein. Because the ASOs prevent expression of the UBE3A protein, treatment with a composition including ASOs of the disclosure may be effective to knock down overexpression of UBE3A.
    Type: Application
    Filed: February 17, 2022
    Publication date: August 18, 2022
    Inventors: James Fink, Luis Williams, Caitlin Lewarch, David Gerber, Duncan Brown, Sudhir Agrawal, Graham T. Dempsey
  • Publication number: 20220230197
    Abstract: A method for facilitating transactions is provided. Various users register their payment modes to avail a payment mode interchange service offered by a server for online purchases. During registration, the users specify corresponding offer amounts in exchange for allowing purchases of other users to be performed by using their payment modes. When an offer on a purchase is not applicable on a payment mode of a first user, the first user is recommended by the server to make the purchase by using a payment mode of a second user on which the offer is applicable. The payment mode of the second user is charged with a purchase amount of the purchase and the offer amount specified by the second user is billed on the payment mode of the first user. The second user receives the offer amount and the first user receives an incentive associated with the offer.
    Type: Application
    Filed: April 7, 2022
    Publication date: July 21, 2022
    Applicant: Mastercard International Incorporated
    Inventors: Rahul Agrawal, Sudhir Gupta, Harsh Piparsaniya
  • Patent number: 11392956
    Abstract: The present disclosure generally relates to systems and methods for processing recurring payment transactions. In various embodiments, the system receives details of the set of recurring payment transactions and stores the details in a recurring transaction details table. The system generates a virtual payment instrument and associates it with the consumer's payment instrument. The system transmits the virtual payment instrument to the consumer. The system then generates a set of payment tokens for the set of recurring transactions and links the tokens to the virtual payment instrument. Each token is associated with a discrete recurring period. The system encodes each token with a sequence of values and stores the tokens in the recurring payment token table. The system receives a recurring transaction request that includes the virtual payment instrument. The system validates the request against a token associated with the recurring period, processes the transaction, and deletes the token.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: July 19, 2022
    Assignee: Mastercard International Incorporated
    Inventors: Harsh Piparsaniya, Sudhir Gupta, Rahul Agrawal
  • Publication number: 20220112496
    Abstract: The invention provides non-opioid pain therapeutic compositions that include an antisense oligonucleotide (ASO) complementary to an identified target on a NaV channel mRNA. The ASO hybridizes to its target RNA and forms a duplex that recruits RNase H to degrade the RNA, thereby downregulating NaV channel synthesis, which inhibits the neuron's ability to contribute to the perception of pain. The ASO targets one of the specific identified targets, and may be provided as a gapmer that includes a central DNA segment flanked by modified RNA wings. When the composition is delivered to dorsal root ganglion (DRG) neurons in vitro, the DRG neurons exhibit a dose-dependent knockdown of NaV1.7, NaV1.8, or NaV1.9.
    Type: Application
    Filed: September 17, 2021
    Publication date: April 14, 2022
    Inventors: Graham T. Dempsey, Owen McManus, Hongkang Zhang, David Gerber, Pin Liu, Dawei Zhang, Duncan Brown, Sudhir Agrawal, Caitlin Lewarch
  • Publication number: 20220088054
    Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
    Type: Application
    Filed: December 6, 2021
    Publication date: March 24, 2022
    Inventors: Sudhir AGRAWAL, Daqing WANG, Wayne JIANG
  • Publication number: 20220073932
    Abstract: The present invention provides an antisense oligonucleotide compound 17 to 25 nucleotides in length comprising at least 12 contiguous nucleobases complementary to an equal length portion of a target RNA sequence, wherein the antisense oligonucleotide compound comprises a 3? domain and a 5? domain, wherein the 3? domain is 10 to 12 nucleotides in length and each nucleotide comprises a deoxyribonucleotide and a phosphodiester or phosphothioate internucleotide linkage or combinations thereof, and wherein the 5? domain is 5 to 15 nucleotides in length, and wherein the 5? domain comprises unmodified deoxyribonucleotides, unmodified ribonucleotides, modified deoxyribonucleotides, modified ribonucleotides, or combinations thereof, provided that the 5? domain comprises at least 1 modified deoxyribonucleotide or modified ribonucleotide comprising a modified sugar and/or backbone. The invention further provides methods of using the antisense oligonucleotide compounds as described herein.
    Type: Application
    Filed: September 17, 2021
    Publication date: March 10, 2022
    Inventor: Sudhir Agrawal
  • Patent number: 11224611
    Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: January 18, 2022
    Assignee: IDERA PHARMACEUTICALS, INC.
    Inventors: Sudhir Agrawal, Daqing Wang, Wayne Jiang
  • Publication number: 20210052625
    Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
    Type: Application
    Filed: September 14, 2020
    Publication date: February 25, 2021
    Inventors: Sudhir AGRAWAL, Daqing WANG, Wayne JIANG
  • Publication number: 20210038630
    Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
    Type: Application
    Filed: October 21, 2020
    Publication date: February 11, 2021
    Inventors: Sudhir AGRAWAL, Daqing WANG, Wayne JIANG
  • Patent number: 10835550
    Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: November 17, 2020
    Assignee: IDERA PHARMACEUTICALS, INC.
    Inventors: Sudhir Agrawal, Daqing Wang, Wayne Jiang
  • Patent number: 10772907
    Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: September 15, 2020
    Assignee: IDERA PHARMACEUTICALS, INC.
    Inventors: Sudhir Agrawal, Daqing Wang, Wayne Jiang
  • Publication number: 20200138848
    Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
    Type: Application
    Filed: August 30, 2019
    Publication date: May 7, 2020
    Inventors: Sudhir AGRAWAL, Daqing WANG, Wayne JIANG
  • Publication number: 20200101102
    Abstract: The invention provides methods of inducing an immune response to cancer comprising co-administering to a cancer patient one or more TLR9 agonists and one or more checkpoint inhibitors. Preferably, the one or more TLR9 agonists are administered to the patient via intratumoral (i.t.) administration.
    Type: Application
    Filed: December 13, 2019
    Publication date: April 2, 2020
    Applicant: IDERA PHARMACEUTICALS, INC.
    Inventors: Daqing WANG, Wayne JIANG, Sudhir AGRAWAL
  • Publication number: 20200054663
    Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
    Type: Application
    Filed: August 30, 2019
    Publication date: February 20, 2020
    Inventors: Sudhir AGRAWAL, Daqing WANG, Wayne JIANG